Skip to main content

Table 3 Univariate analysis

From: Bendamustine in patients with relapsed or refractory multiple myeloma

  EFS OS
ISS stage (I vs. II+II) 0.2 0.001
Cytogenetics (normal vs. abnormal karyotype) 0.05 0.2
LDH (</> 200 U/l) 0.5 0.02
CRP (</> 0.6 mg/dl) 0.7 0.001
Haemoglobine level (</> 10 g/dl) 0.2 0.04
Platelet count (</> 200.000/μl) 0.6 0.1
Chemosensitivity (relapse vs. refractory) 0.4 0.01
Prior thalidomide 0.4 1.0
Prior high-dose therapy 0.5 0.4
Extramedullary manifestation 0.4 0.2
Osteolytic lesions 0.5 0.3
Bendamustine dosage </> 120 mg/m2 0.6 0.9
Monotherapy vs. Steroid combination therapy 0.7 0.3